Typ 1 Diabetes im Vorstadium stoppen? ABATACEPT-Studie
Drug Insight: abatacept for the treatment of rheumatoid arthritis | Nature Reviews Rheumatology
Arthritis drug abatacept slows type 1 diabetes progression - Diabetes
Diabetes Mellitus Typ 1: Durch Immunmodulation verhindern?
Aktuell Lesenswertes - Deutsche Autoimmun-Stiftung
Uncovering Pathways to Personalized Therapies in Type 1 Diabetes
CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes
Artikel Deutsches Ärzteblatt
JCI Insight - B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes
Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease | American Journal of Physiology-Renal Physiology
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial - The Lancet
Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes | Nature Immunology
Typ 1 Diabetes im Vorstadium stoppen? ABATACEPT-Studie
New Frontiers in the Treatment of Type 1 Diabetes - ScienceDirect
Diabetology | Free Full-Text | Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes
Abatacept decreases TFH cells during an ongoing autoimmune response in... | Download Scientific Diagram
Fighting the uphill battle to cure type 1 diabetes - Lee - 2021 - Journal of Diabetes Investigation - Wiley Online Library
News
Abatacept Lowers Diabetes Risk in RA
ORENCIA® (abatacept) | Official Patient Website
Erhöhtes Diabetesrisiko bei Patienten mit rheumatoider Arthritis
JCI Insight - B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes
Growing up with TrialNet — Screened as children and now in their 20s, two Abatacept Prevention Study participants share their stories | TRIALNET Type 1 Diabetes TrialNet
A machine learning approach to predict response to immunotherapy in type 1 diabetes | Cellular & Molecular Immunology
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial - The Lancet